AU2022464309A1 - Prophylactic drug and therapeutic drug for diabetes-associated dementia - Google Patents

Prophylactic drug and therapeutic drug for diabetes-associated dementia Download PDF

Info

Publication number
AU2022464309A1
AU2022464309A1 AU2022464309A AU2022464309A AU2022464309A1 AU 2022464309 A1 AU2022464309 A1 AU 2022464309A1 AU 2022464309 A AU2022464309 A AU 2022464309A AU 2022464309 A AU2022464309 A AU 2022464309A AU 2022464309 A1 AU2022464309 A1 AU 2022464309A1
Authority
AU
Australia
Prior art keywords
diabetes
lps
drug
stz
associated dementia
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2022464309A
Other languages
English (en)
Inventor
Hiroyuki Inagawa
Chie Kohchi
Haruka MIZOBUCHI
Gen-Ichiro Soma
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biomedical Research Group Inc
Original Assignee
Biomedical Research Group Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biomedical Research Group Inc filed Critical Biomedical Research Group Inc
Publication of AU2022464309A1 publication Critical patent/AU2022464309A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/739—Lipopolysaccharides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A61K35/741—Probiotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Hospice & Palliative Care (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
AU2022464309A 2022-06-22 2022-06-22 Prophylactic drug and therapeutic drug for diabetes-associated dementia Pending AU2022464309A1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/JP2022/024854 WO2023248374A1 (ja) 2022-06-22 2022-06-22 糖尿病性認知症に対する予防薬及び治療薬

Publications (1)

Publication Number Publication Date
AU2022464309A1 true AU2022464309A1 (en) 2025-01-23

Family

ID=89379623

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2022464309A Pending AU2022464309A1 (en) 2022-06-22 2022-06-22 Prophylactic drug and therapeutic drug for diabetes-associated dementia

Country Status (5)

Country Link
US (1) US20250381216A1 (https=)
JP (1) JPWO2023248374A1 (https=)
KR (1) KR20250025712A (https=)
AU (1) AU2022464309A1 (https=)
WO (1) WO2023248374A1 (https=)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8075928B2 (en) * 2003-09-26 2011-12-13 Gen-Ichiro Soma Method for fermentation and cultivation, fermented plant extract, fermented plant extract powder, and composition containing the extract of fermented plant
AU2006326642B2 (en) * 2005-12-09 2012-05-03 Technion Research And Development Foundation Ltd. Use of low-dose ladostigil for neuroprotection
CN108567792A (zh) * 2017-03-07 2018-09-25 上海泽生科技开发股份有限公司 一种治疗阿尔茨海默病的复合维生素组合物
JP6998133B2 (ja) * 2017-05-28 2022-01-18 自然免疫制御技術研究組合 リポ多糖を用いた脳機能改善剤、食品及び医薬品
JP6861264B1 (ja) * 2019-11-19 2021-04-21 慶昌 木島 組成物

Also Published As

Publication number Publication date
KR20250025712A (ko) 2025-02-24
WO2023248374A1 (ja) 2023-12-28
JPWO2023248374A1 (https=) 2023-12-28
US20250381216A1 (en) 2025-12-18

Similar Documents

Publication Publication Date Title
JP6676062B2 (ja) 認知低下を処置するための方法
Molaei et al. Synergistic effects of quercetin and regular exercise on the recovery of spatial memory and reduction of parameters of oxidative stress in animal model of Alzheimer's disease
Rasoolijazi et al. The beneficial effect of (-)-epigallocatechin-3-gallate in an experimental model of Alzheimer’s disease in rat: A behavioral analysis
Wang et al. Corilagin ameliorates sleep deprivation-induced memory impairments by inhibiting NOX2 and activating Nrf2
Li et al. Lipoic acid protects dopaminergic neurons in LPS-induced Parkinson’s disease model
Salmani et al. Angiotensin receptor blocker, losartan ameliorates neuroinflammation and behavioral consequences of lipopolysaccharide injection
Wei et al. Ghrelin inhibits proinflammatory responses and prevents cognitive impairment in septic rats
Wang et al. Nicotinamide mononucleotide administration after sever hypoglycemia improves neuronal survival and cognitive function in rats
GB2523044A (en) Antidementia and learning/memory function-improving drug
Cheng et al. Insulin injections inhibits PTZ-induced mitochondrial dysfunction, oxidative stress and neurological deficits via the SIRT1/PGC-1α/SIRT3 pathway
CN110559282A (zh) 去甲氯胺酮在制备抗抑郁的药物中的应用
Yarar-Fisher et al. Ketogenic regimens for acute neurotraumatic events
Xiu-Jing et al. Effects of chronic administration of melatonin on spatial learning ability and long-term potentiation in lead-exposed and control rats
KR20150050406A (ko) 니코틴아마이드 라이보사이드를 유효성분으로 포함하는 패혈증 치료 또는 예방용 약제학적 조성물
Zhang et al. Okadaic acid blocks the effects of 5-aza-2-deoxycytidine on consolidation, acquisition and retrieval of morphine-induced place preference in rats
AN et al. Exploring the potential of bioactive compounds as interventions for dementia: current insights and future directions
US20250381216A1 (en) Prophylactic drug and therapeutic drug for diabetes-associated dementia
US9789092B2 (en) Biotin for use in treating X-linked adrenoleukodystrophy
Fang et al. Long-term aerobic exercise reduces tau phosphorylation by activating the PI3K/AKT pathway in the hippocampus of APP/PS1 mice
CN117357563A (zh) 灭活鼠乳杆菌在制备预防和/或治疗异动症药物中的应用
CN114796181A (zh) 益母草碱在制备用于防治非血管性痴呆或感染性中枢神经损伤的药物中的应用
US20090258951A1 (en) Use of vanillyl alcohol for the treatment of Parkinson's disease
US9662367B2 (en) Adaptogenic compositions and method for production thereof
CA3100649C (en) Use of pharmaceutical composition including clavulanic acid and valproic acid to treat epilepsy seizure, and/or to treat epilepsy-associated motor symptom and cognitive impairment
CN105168201B (zh) 牡荆素在制备治疗术后疼痛药物中的应用